Articles tagged with Melanoma
Researchers have identified the ATG5 protein as a key regulator of metastatic capacity in melanomas. The study found that patients with partial loss of the ATG5 gene have a worse prognosis, developing metastasis and resistance to drugs.
Researchers discovered that melanoma sends tiny vesicles containing microRNA before spreading, inducing morphological changes in the dermis. They found promising chemical substances to block this process, offering hope for a cure for the deadly disease.
New research links specific inherited genetic differences to an increased risk for eye melanoma, a rare form of melanoma arising from pigment cells that determine eye color. Genetic mutations associated with skin melanoma were also found to be linked to uveal melanoma risk.
A retrospective clinical study found that patients with melanoma who received both ipilimumab and local peripheral treatments had significantly prolonged overall survival compared to those who received only ipilimumab. The median overall survival for these patients was 93 weeks, compared to 42 weeks for those receiving only ipilimumab.
A task force has been criticized for not recommending melanoma screening due to lack of evidence, but dermatologists believe early detection reduces risk of death from melanoma through visual inspections. The issue highlights the need for refined standards on skin cancer screenings with potential life-saving benefits.
A new study of over 1,000 primary care melanoma screenings found no significant increase in surgical treatments or specialist referrals. The practice did result in a 79% increase in per-patient melanoma diagnoses among the most trained group, but this was not associated with an increase in dermatologist visits or surgeries.
Patients with melanoma and their partners can help detect early signs of a second primary melanoma with skin self-examination. A clinical trial found that trained partners identified 43 new melanomas, compared to none in the control group.
Regular skin checks during PCP visits improve melanoma detection and treatment outcomes. Thinner melanomas detected through screening have a better prognosis than thicker ones.
Researchers successfully treated a patient with metastatic melanoma using a combined approach of immunotherapy, including IL-21-primed polyclonal CTL plus CTLA4 blockade. The treatment led to the complete disappearance of tumors and sustained disease-free status for five years.
Researchers found that a tumor suppressor gene helps repair UV damage in cells, reducing the risk of skin cancers like melanoma. The study suggests this gene may serve as a biomarker for skin cancer prevention and offers hope for new drug targets.
A study by Sanford Burnham Prebys Medical Discovery Institute identified a super-oncogenic protein, activating transcription factor 2 (ATF2), that drives the formation of melanoma in mice with BRAF mutations. Inactive ATF2 was found to cause tumors to develop slower than expected, making it a potential indicator of tumor aggressiveness.
A multicenter prospective study found that untreated severe obstructive sleep apnea is associated with increased aggressiveness of malignant cutaneous melanoma. The study involved 412 patients and showed a relationship between sleep apnea and poor prognosis markers for melanoma.
Research suggests that melanomas from the South Island of New Zealand are more likely to carry gene mutations affecting treatment outcomes. The study found significantly higher rates of NRAS mutations in South Island patients compared to those from the North Island, with implications for targeted drug therapies and patient outcomes.
Dr. Murtaza and Dr. Antoni Ribas are awarded $200,000 to investigate whether microbiome analysis can predict patient response to immunotherapy in melanoma patients. Their study aims to analyze the relationship between microbial composition and immunotherapy outcomes.
The white paper outlines key takeaways, including the importance of proper sunscreen use to reduce melanoma risk by up to 50%, developing more precise diagnosis methods, and overcoming immunotherapy resistance. The research aims to advance treatment and potentially cure melanoma by understanding its unique characteristics.
A hospital-based study found carriers of MC1R variants were at higher risk of melanoma, regardless of sun exposure. The study suggests a potential molecular mechanism underlying melanoma development.
Researchers developed a microneedle patch that delivers anti-PD-1 antibodies directly to the site of melanoma skin cancer, improving treatment effectiveness. The patch creates a sustained release of antibodies into the tumor microenvironment, achieving better retention and efficacy compared to traditional treatments.
Researchers at VIB, KU Leuven and UGent have discovered a non-coding RNA gene called SAMMSON that is specifically expressed in human malignant melanoma. The growth of aggressive skin cancer is highly dependent on this gene, paving the way for improved diagnostic tools and treatment options.
A new blood test can detect early warning signs of skin cancer relapse in advanced melanoma patients by tracking levels of circulating tumour DNA. The test identifies new mutations in genes like NRAS and PI3K, which may cause the relapse.
Most melanoma patients had zero to 20 total moles and no atypical moles. In younger patients under 60, having few total moles reduced the risk of thick melanomas, while having more atypical moles increased tumor thickness.
A new biomarker, PRAME mRNA, has been identified as a key indicator of high-risk uveal melanoma patients who are more likely to develop metastasis. This discovery may lead to the development of precision medicines for melanoma patients.
Current diagnostic techniques make aggressive treatment unnecessary for many patients with metastasized skin cancer. The Sunbelt Melanoma Trial found that interferon therapy offered no benefits for stage III melanoma patients with minimal lymph node involvement.
A study published in JAMA Dermatology found that women younger than 40 who were diagnosed with melanoma had initiated indoor tanning at an earlier age and reported more frequent tanning. The study suggests that indoor tanning is a significant risk factor for developing melanoma, especially among young women.
Researchers discovered a significant link between pregnancy and higher risk of melanoma, including increased death rates, metastasis, and recurrence.
Researchers discovered an inherited genetic marker associated with less favorable melanoma survival, while another variant showed a stronger correlation with better survival. These findings could lead to the development of personalized treatment plans for high-risk patients.
Researchers have developed a class of compounds that inhibit acid ceramidase, an enzyme that accelerates tumor growth in melanoma. These compounds enhance the effect of anti-tumor drugs by making melanoma cells more prone to apoptosis.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a promising new melanoma drug, SBI-756. The compound targets the translation initiation complex and has been shown to inhibit melanoma cell growth. SBI-756 may offer a significant advantage in overcoming tumor resistance.
A new study maps out the genetic changes in melanoma development, confirming sun exposure's role and identifying an intermediate disease stage between benign moles and malignancy. The research provides evidence of UV-induced mutations in benign lesions, precursor lesions, and melanoma, highlighting the importance of sun protection.
Researchers at King's College London have identified a method to quickly estimate total body mole count using a smaller 'proxy' area, like the arm. Females with over 7 moles on their right arm had 9 times more risk of having 50+ moles overall, while those with 11 or more had 100+, indicating higher melanoma risk.
A new study shows that surgical removal of abdominal metastases can significantly improve overall survival for patients with stage IV melanoma. In this comprehensive study of over 1,600 patients, surgeons found that surgical resection provided a median survival time of 18 months compared to seven months for nonsurgical patients.
A study found that training patients with melanoma and their partners on skin examinations increased patient self-efficacy in performing self-examinations. The intervention showed the greatest benefit for pairs with low relationship quality and limited time together.
A combination of dabrafenib and trametinib significantly prolongs median overall survival time for advanced melanoma patients to over two years, with 51% remaining alive after two years. The treatment also improves disease-free progression and quality of life compared to vemurafenib alone.
Researchers found that the combination therapy improved progression-free survival across various sub-groups, including those with poor prognostic factors. The study also showed similar efficacy regardless of BRAF mutation status and disease stage.
A new report by Eliezer Van Allen and colleagues found that melanoma patients who benefit from ipilimumab immunotherapy have unique tumor-produced antigens. The study suggests that predicting which patients will respond to the treatment may be challenging due to differences in molecular targets.
Organ transplant recipients are more susceptible to developing regional stage melanoma due to immunosuppressive medications. The study found that transplant patients were four times more likely to be diagnosed with regional stage melanoma and three times more likely to die from the disease.
Researchers at UC Davis found that a novel combination therapy of Interleukin (IL)-2 combined with imiquimod and topical retinoid is highly effective in treating patients with skin metastases, resulting in complete clinical response and high survival rates.
The University of Kentucky's Dr. John D'Orazio is leading a 3-year research project on melanoma, the deadliest form of skin cancer, with a focus on hormonal pathways and DNA repair. The study aims to understand how specific hormones affect melanocortin1 receptor signaling, which is linked to an increased risk of developing melanoma.
Scientists have uncovered five new common genetic risk factors for melanoma and confirmed two others, establishing the role of telomeres in its development. Skin pigmentation is also a key genetic determinant, emphasizing the importance of sun protection for individuals with pale skin and many moles.
A Yale study identified NF1 as a key gene in melanoma development and progression. The research revealed that 45% of melanomas without known BRAF or NRAS mutations display loss of NF1 function, leading to cancer-causing pathways.
Researchers Neil Ganem and Anurag Singh at Boston University School of Medicine are developing new strategies to inhibit the growth of chromosomally unstable cancer cells expressing oncogenic BRAF. They have identified two major types of NRAS networks in melanoma, which may be targeted with selective anti-cancer agents.
A large analysis suggests frequent citrus fruit and juice consumption may increase melanoma risk by 36% in people who eat them daily. The association is strongest for grapefruit, but not processed juices.
A study found that use of phosphodiesterase type 5 inhibitors for erectile dysfunction was associated with a modest but significant increased risk of malignant melanoma in Swedish men. The most pronounced increase in risk was observed in men who had filled a single prescription, but not among those with multiple prescriptions.
Researchers from Umea University found no association between PDEi drugs and increased melanoma risk; instead, men taking these drugs are more health-conscious and sunbathe more often, increasing their melanoma diagnosis risk.
Google searches for information on melanoma and skin cancer rose over summer months from 2010 to 2014. The correlation between these searches and actual melanoma incidence and mortality rates was limited, suggesting that increased search volumes do not necessarily translate to improved detection rates.
Clinical trials demonstrate improved survival rates for patients with metastatic melanoma using immune therapies nivolumab and pembrolizumab. These treatments target the 'don't attack' protein PDL1 on tumors, allowing the immune system to prime against tumor tissue.
Researchers found that combining immunotherapy drugs nivolumab and ipilimumab significantly increases progression-free survival in advanced melanoma patients, with a median PFS of 11.5 months compared to 6.9 months for nivolumab alone.
Nivolumab has shown promise as a therapeutic agent for improving survival rates in melanoma patients. The most common adverse events were fatigue, pruritus, diarrhea, and rash, which were primarily low-grade and manageable with immunomodulatory agents.
Researchers found traditional teaching methods focus on factual knowledge rather than visual training, leading to improved results with perceptual training modules. Undergraduate students reached expertise in identifying skin cancers and benign lesions within two hours of training.
Researchers from NYU Langone present 30 abstracts on various cancer types, including immunotherapy studies for melanoma and pediatric leukemia. Key findings highlight the potential for personalized medicine and improved outcomes in cancer patients.
A phase 3 international trial found that ipilimumab improved recurrence-free survival in advanced stage melanoma patients who underwent surgical resection. The study showed that patients with microscopic metastatic disease responded best to ipilimumab treatment.
Researchers found hundreds of possible new genes that could transform benign skin growths into deadly melanomas when combined with the Braf V600E mutation. The discovery provides new targets for slowing or stopping cancer growth.
A recent EORTC trial found that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence. However, the treatment was also associated with a high rate of immune-related adverse events.
A multicenter clinical trial launched by Yale University aims to evaluate the effectiveness of personalized medicine in treating metastatic melanoma. The trial will enroll patients lacking a particular genetic mutation and use molecular sequencing techniques to match targeted drugs to unique genetic alterations.
Researchers have linked a new protein, megalin, to aggressive malignant melanoma cells that are more likely to spread. The protein's presence can improve cancer cell division and survival, making it a potential marker for early detection and targeted treatment options.
Researchers found a decrease in pediatric melanoma cases in the US from 2000-2010, with an overall decline of 12% per year. The number of new cases decreased in boys and adolescents, particularly those with good prognostic indicators.
A Yale study found that one in five Medicare patients with melanoma experience significant delays in getting surgery, affecting their psychological well-being and healthcare quality. The study analyzed data from over 32,000 Medicare patients and revealed that 22% waited longer than 1.5 months for treatment.
A study of 32,501 melanoma cases found that 1 in 5 patients experienced a delay of surgery lasting longer than 1.5 months. Surgical delays were more common among older patients and those with prior melanoma or multiple medical conditions.
Researchers found that Nodal protein promotes melanoma cell growth and survival, leading to improved treatment outcomes with anti-Nodal antibody combinations. The study provides hope for patients with metastatic melanoma, a disease with limited treatment options.
A case-control study of over 180,000 men found that men with testicular cancer have a higher incidence of prostate cancer compared to those without a history of the disease. The study revealed a significant increase in aggressive prostate cancers among men with testicular cancer.
Researchers at MD Anderson Cancer Center have identified unique 'protein patterns' in melanoma patients to predict resistance to BRAF inhibitors. These patterns may help guide personalized treatment decisions, including targeted agents or immunotherapies.